Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Its March 20 $29 put had the highest unusual options activity on the day with a Vol/OI (volume-to-open-interest) ratio of 210 ...

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both numbers came in well above expectations, with diluted EPS $0.20 higher than ...

Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...

After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup. As the company continues to adapt to a ...

Pfizer last month completed an acquisition of biotech firm Metsera, deepening its portfolio of products in the fast-growing market for weight loss drugs - Copyright ...

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...

After reporting record revenue a few years ago, Pfizer has faced tougher times in recent quarters. Challenges include a decline in demand for coronavirus products and patent expirations on the horizon ...